TP53 and neoplasm: Moreover, PRIMA-1 was tested on 34 human tumor cell lines of different tissues from the National Cancer Institute database and compared with five known anticancer drugs; PRIMA-1 was found to preferentially inhibit the growth of cell lines carrying TP53 mutations as compared with cells expressing wild-type P53.